PSMA-ADT (ARSI) – Prostate Cancer
Lay Title: An imaging study to evaluate the effects of hormonal treatments on prostate cancer imaging with PSMA PET.
Technical Title: Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with metastatic castrate-resistant prostate cancer: a prospective exploratory study
Disease Type: Metastatic castrate-resistant prostate cancer (mCRPC)
Basic information: The purpose of this research study is to monitor the PSMA PET signal intensity at different time points after initiation of hormonal treatment with androgen receptor signaling inhibitors (ARSI): Enzalutamide or Abiraterone or Apalutamide. Patients with metastatic castrate-resistant prostate cancer (mCRPC) scheduled for treatment with ARSI will undergo serial PSMA PET/CT scans and serum PSA monitoring. The duration of the study is up to 1 year from initiation of the hormonal treatment.
Research Procedures: This Trial will enroll 30 patients with mCRPC who are scheduled to initiate treatment with ARSI (i.e. Enzalutamide, Abiraterone or Apalutamide).
All patients will receive a at least 3 PSMA scan and 3 PSA serum measurements in the Nuclear Medicine clinic:
Each patient will then be followed up with regular serum PSA measurements every three months (as per standard-of-care) for up to 1 year. In case biochemical recurrence of disease (BCR) is detected during follow-up the patient will undergo a 4th and last PSME PET (Visit #4) at time of BCR.
All PSMA PET/CT scans and PSA measurements during the visits in the nuclear medicine clinic will be free of charge.
More detailed information on ClinicalTrials.gov >
For More Detailed Information, Contact: